Studying coagulation in COVID-19 using blood-vessel-on-chip technology.

Studying coagulation in COVID-19 using blood-vessel-on-chip technology. - COV-AGULATE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51031

Enrollment

Registered

2020-12-21

Start date

2021-01-26

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

increased coagulation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1) Age >18 yr or older 2) Suspected SARS-CoV-2 infection 3) Need for oxygen supplementation 4) CRP-level * 50 mg/L 5) D-dimer level *1.0 mg/L 6) Ability to provide written informed consent

Exclusion criteria

Exclusion criteria: 1) History of venous thromboembolism 2) Use of anticoagulant therapy at inclusion 3) Known hereditary or acquired thrombophilia

Design outcomes

Primary

Measure	Time frame
The primary outcome will be in situ platelet aggregation and coagulation measured using the blood-vessel-on-chip technology.	—

Secondary

Measure	Time frame
Secondary outcomes include changes in gene expression profiles in the chip, and markers of coagulopathy (e.g. D-dimer) and neutrophil extracellular traps (e.g. citrullinated histone H3).	—

Countries

Netherlands

Outcome results